[1]Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2]Siegel R L, Miller K D, Fuchs H E, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33.
[3]Nouhi M, Mousavi S M, Olyaeemanesh A, et al. Long-term clinical outcomes of radical prostatectomy versus watchful waiting in localized prostate cancer patients: a systematic review and meta-analysis[J]. Iran J Public Health, 2019, 48(4): 566-578.
[4]Lantz A, Bock D, Akre O, et al. Functional and oncological outcomes after open versus robot-assisted laparoscopic radical prostatectomy for localised prostate cancer: 8-year follow-up[J]. Eur Urol, 2021, 80(5): 650-660.
[5]Moreira D M, Presti J C, Jr, Aronson W J, et al. Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases[J]. Int J Urol, 2010, 17(11): 914-922.
[6]García Cortés , Colombás Vives J, Gutiérrez Castaé C, et al. Comparison of surgical approaches to radical prostatectomy in our series beyond oncological and functional outcomes[J]. Actas Urol Esp (Engl Ed), 2022, 46(5): 275-284.
[7]Brassetti A, Bollens R. Laparoscopic radical prostatectomy in 2018: 20 years of worldwide experiences, experimentations, researches and refinements[J]. Minerva Chir, 2019, 74(1): 37-53.
[8]Hruza M, Bermejo J L, Flinspach B, et al. Long-term oncological outcomes after laparoscopic radical prostatectomy[J]. BJU Int, 2013, 111(2): 271-280.
[9]Busch J, Stephan C, Herold A, et al. Long-term oncological and continence outcomes after laparoscopic radical prostatectomy: a single-centre experience[J]. BJU Int, 2012, 110(11 Pt C): E985-E990.
[10]Freedland S J, Partin A W, Humphreys E B, et al. Radical prostatectomy for clinical stage T3a disease[J]. Cancer, 2007, 109(7): 1273-1278.
[11]高新, 江东根, 黄群雄, 等. 根治性前列腺切除联合扩大盆腔淋巴结清扫术治疗局部高危前列腺癌12年经验总结[J]. 中华泌尿外科杂志, 2017, 38(6): 433-437.
[12]王喻, 孙卓伦, 李腾成, 等. 扩大盆腔淋巴结清扫+前列腺癌根治术治疗局部高危前列腺癌十年随访结果[J]. 中华腔镜泌尿外科杂志: 电子版, 2022, 16(2): 101-105.
[13]Sakai I, Harada K I, Kurahashi T, et al. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer[J]. Urol Int, 2006, 76(3): 227-231.
[14]Nakamura M, Hasumi H, Miyoshi Y, et al. Usefulness of ultrasensitive prostate-specific antigen assay for early detection of biochemical failure after radical prostatectomy[J]. Int J Urol, 2005, 12(12): 1050-1054.
[15]Moreira D M, Presti J C, Jr, Aronson W J, et al. Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database[J]. BJU Int, 2010, 105(11): 1541-1547.
[16]Ghabili K, Park H S, Yu J B, et al. National trends in the management of patients with positive surgical margins at radical prostatectomy[J]. World J Urol, 2021, 39(4): 1141-1151.
[17]Rassweiler J, Stolzenburg J, Sulser T, et al. Laparoscopic radical prostatectomy—the experience of the German Laparoscopic Working Group[J]. Eur Urol, 2006, 49(1): 113-119.
[18]Coelho R F, Rocco B, Patel M B, et al. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a critical review of outcomes reported by high-volume centers[J]. J Endourol, 2010, 24(12): 2003-2015.
[19]Salter C A, Tin A L, Bernie H L, et al. Predictors of worsening erectile function in men with functional erections early after radical prostatectomy[J]. J Sex Med, 2022, 19(12): 1790-1796.
|